Key Highlights
- Stereotaxis issued 1,469,485 common shares and pre‑funded warrants for 4,575,143 shares to Robocath holders as part of the July 7 2026 closing.
- A financial advisor received 225,000 Stereotaxis shares as partial payment of a success fee linked to the acquisition.
- Earnout provisions may trigger additional equity or cash up to $25.0 million, but total new shares will not exceed 19.9% of pre‑transaction outstanding shares without shareholder approval.
Stereotaxis (NYSE American: STXS) announced on July 9 2026 that it had closed its purchase of French‑based Robocath.
Deal Structure
The transaction was guided by a Share Sale Agreement dated April 14 2026, under which Stereotaxis acquired other securities collectively representing 100% of Robocath’s voting power. The agreement outlined the mix of cash consideration and equity issuance, as well as the framework for potential earnout payments. This acquisition strengthens Stereotaxis’ footprint in the catheter‑based cardiac therapy market, a segment that continues to grow as hospitals seek minimally invasive solutions for arrhythmia treatment.
Complementing the share issuance, the company also granted “pre‑funded” warrants (the “Purchaser Warrants”) that allow holders to acquire 4,575,143 shares at the par‑value price. The warrants are exercisable at any time from issuance through July 7 2031, giving participants a direct pathway to increase their stake in Stereotaxis.
Advisor Compensation
Robocath’s financial advisor was compensated with 225,000 Stereotaxis shares, issued alongside the closing. This equity‑based fee aligns the advisor’s interests with the longer‑term performance of the combined businesses and reflects the advisory services rendered in structuring the transaction.
Earnout Contingency
The Share Sale Agreement sets forth performance‑based earnout targets that could result in additional equity or cash consideration not to exceed $25.0 million. Any extra issuance will be calculated based on Stereotaxis’ market price at the time of payment and will be capped at 19.9% of the pre‑acquisition share count unless shareholders authorize a higher dilution. This mechanism ties future compensation to the successful integration of Robocath’s technology platform and the achievement of specified revenue milestones.
Regulatory Compliance
Stereotaxis relied on representations that the recipients of the newly issued securities qualified as accredited investors under Regulation D or as non‑U.S. Persons under Regulation S. The company plans to file a resale registration statement covering the issued shares and any potential earnout‑related issuances, thereby meeting the SEC’s disclosure obligations for unregistered equity transactions.
Market Impact
The combined issuance of shares and warrants expands Stereotaxis’ outstanding equity, yet the dilution remains below the 19.9% threshold without further shareholder consent. Industry observers will watch the integration of Robocath’s catheter technology, which aims to enhance electrophysiology procedures, and the fulfillment of earnout milestones, as both factors could shape future share counts and cash flow dynamics.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.


_11_19_2026_12_58_12_592184.jpg)



Please wait processing your request...